Business
Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
Jun. 28, 2011 (Canada NewsWire Group) -- TSX Exchange Symbol: RVX CALGARY, June 28, 201...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n Jun. 28, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, June 28, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix")\n (TSX:RVX) announces today the presentation of additional new findings\n arising from analysis of data gathered in the Phase 2 ASSERT trial at\n the annual meeting of the European Atherosclerosis Society (EAS) in\n Gothenburg, Sweden.  The EAS is a prestigious meeting that brings\n together both clinicians and scientists to share new knowledge in the\n battle against atherosclerosis.  At the EAS, there were two\n presentations co-authored by prominent scientists from Resverlogix's\n Clinical Steering Committee.\n\n\nResverlogix's previous studies have demonstrated RVX-208 to be an orally\n active small molecules that raises Apolipoprotein A-I (apoA-I)\n production.  In the recently completed ASSERT trial, Resverlogix\n illustrated that RVX-208 enhanced biomarkers of reverse cholesterol\n transport (RCT) in keeping with its unique mechanism of action.  The\n on-going analysis of the ASSERT data yielded new findings that formed\n the substance of an EAS presentation entitled "Anti-Inflammatory\n Effects of a Novel Inducer of Apolipoprotein A-I Synthesis: Insights\n from the ASSERT Study" showing the potential role of RVX-208 in\n lowering hsCRP, a well-known biomarker of inflammation which is an\n important process in the pathogenesis of atherosclerosis.\n\n\nDr. Jan Johansson, Resve...